These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 28888400)

  • 1. Characterization of inflammasome-related genes in urine sediments of patients receiving intravesical BCG therapy.
    Poli G; Cochetti G; Boni A; Egidi MG; Brancorsini S; Mearini E
    Urol Oncol; 2017 Dec; 35(12):674.e19-674.e24. PubMed ID: 28888400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of inflammasome-related genes in bladder cancer and their association with cytokeratin 20 messenger RNA.
    Poli G; Brancorsini S; Cochetti G; Barillaro F; Egidi MG; Mearini E
    Urol Oncol; 2015 Dec; 33(12):505.e1-7. PubMed ID: 26282902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
    Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
    Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.
    Giannarini G; Birkhäuser FD; Recker F; Thalmann GN; Studer UE
    Eur Urol; 2014 Apr; 65(4):825-31. PubMed ID: 24144432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
    Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
    Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T; Bohin D; Kassardjian Z; Herve JM; Molinie V; Barre P; Lugagne PM; Botto H
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
    Martínez-Piñeiro L; Portillo JA; Fernández JM; Zabala JA; Cadierno I; Moyano JL; Solsona E; Unda M; Beardo P; Rodríguez-Molina J; Chantada V; Palou J; Muntañola P; Alonso Dorrego JM; Pérez-Garcia FJ; Silva JM; Chesa N; Montesinos M; Ojea A; Madero R; Martínez-Piñeiro JA
    Eur Urol; 2015 Aug; 68(2):256-62. PubMed ID: 25794457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ; Shen ZJ; Lu J; Jin XD; Chen J; Shi SF
    Zhonghua Wai Ke Za Zhi; 2005 Nov; 43(22):1457-60. PubMed ID: 16318813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage combination intravesical immunotherapy with Bacillus Calmette-Guérin and interferon-α2B: impact on recurrence, progression, and survival.
    Prasad SM; Eyre S; Loughlin KR
    Hosp Pract (1995); 2013; 41(4):31-9. PubMed ID: 24145587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single-institution experience with induction and maintenance intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to bacille Calmette-Guérin therapy.
    Barlow L; McKiernan J; Sawczuk I; Benson M
    BJU Int; 2009 Oct; 104(8):1098-102. PubMed ID: 19389012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical bacillus Calmette-Guerin (BCG) instillation for primary and recurring T1G3 bladder cancers.
    Okamura T; Akita H; Ando R; Kawai Y; Tozawa K; Kohri K
    Asian Pac J Cancer Prev; 2010; 11(4):1107-10. PubMed ID: 21133632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
    Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
    Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment.
    Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K
    Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
    Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
    Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of neural precursor cell-expressed developmentally down-regulated protein 9 in predicting bacillus Calmette-Guerin response in nonmuscle invasive bladder cancer.
    El-Babouly IM; Desoky EAE; El Sayed D; Ali MM; Harb OA; Ragab A; Sakr AM; Fawzi AM; Salama NM; Samaha II
    Urol Oncol; 2018 May; 36(5):242.e9-242.e14. PubMed ID: 29519561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of subsequent tumour recurrence and stage progression in bacille Calmette-Guérin relapsing non-muscle-invasive bladder cancer.
    Matsumoto K; Kikuchi E; Shirakawa H; Hayakawa N; Tanaka N; Ninomiya A; Miyajima A; Nakamura S; Oya M
    BJU Int; 2012 Dec; 110(11 Pt B):E508-13. PubMed ID: 22574662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.